A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This study will test the safety and efficacy of FOR46 given every 21 days to patients with
relapsed or refractory multiple myeloma.
The name of the study drug involved in this study is: FOR46 for Injection